This study is currently recruiting.
Description: This research study is being conducted to determine the efficacy of guanfacine immediate release (GIR) for the treatment of hyperactivity/impulsivity and inattention in children with Down Syndrome (DS) ages 6-12 years old after 8 weeks of treatment.
Eligibility & Criteria
IRB #: IRB00435979
Principal Investigator: George Capone, MD
Eligible Age Range: 6 to 12 years Gender: All
Diagnosis: Non-mosaic Down Syndrome, ADHD symptoms